New drug combo aims to boost immune attack on Hard-to-Treat myeloma
NCT ID NCT06622005
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-phase trial tests whether adding an experimental drug called SX-682 to a standard three-drug regimen is safe for people with multiple myeloma that has relapsed or become resistant. SX-682 works by freeing up immune cells to better kill cancer cells. The study will enroll about 15 participants and closely monitor side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SX-682 (a drug that blocks certain immune cell signals) combined with carfilzomib, daratumumab-hyaluronidase, and dexamethasone
- What this could lead to
- If successful, this could point toward a new combination treatment option for patients with multiple myeloma that has returned or not responded to prior therapy.
- What could go wrong
- This is a very early (Phase 1) trial with only 15 participants, so the main goal is safety, not effectiveness. The combination may cause side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- Can a drug stop dangerous side effects of new myeloma therapies?